Steve Ubl, president and CEO of AdvaMed will leave his post at AdvaMed in the fall to serve as president and CEO of PhRMA.
Ubl shared the letter below with the AdvaMed Board of Directors on Friday, September 25, 2015.Continue reading
Steve Ubl, president and CEO of AdvaMed will leave his post at AdvaMed in the fall to serve as president and CEO of PhRMA.
Ubl shared the letter below with the AdvaMed Board of Directors on Friday, September 25, 2015.Continue reading
The latest updates from Capitol Hill as provided by BIO and Republic Consulting Group.
Continue reading
The Safe and Accurate Food Labeling Act will ensure that food labeling in the United States is consistent across state lines and based on sound science. Continue reading
Bipartisan action on July 14, 2015 by the U.S. House Agriculture Committee advances the Safe and Accurate Food Labeling Act (H.R. 1599).Continue reading
In a 344 to 77 vote, the U.S. House of Representatives passed H.R.6: The 21st Century Cures Act on the morning of July 10, 2015. Continue reading
21st Century Cures passes unanimously out of the House Energy and Commerce Committee.
“AZBio congratulates Members of the House Energy and Commerce Committee and all of the representatives of industry, patients, and our key federal agency partners on a truly collaborative effort to progress H.R. 6 – The 21st Century Cures Act.” Joan Koerber-Walker, President & CEO, Arizona Bioindustry Association (AZBio) and Chair, AdvaMed State Medical Technology Alliance Continue reading
America’s medical technology industry creates life-saving and life-enhancing treatments and cures that drive efficiencies and cost savings in the health care system, improve the quality of patient care, and generate high-quality jobs that contribute to economic growth. But today, the innovation ecosystem that supports medical technology development is severely stressed. The U.S. has historically been the world leader in medical technology, but our leadership is eroding. To respond to these challenges, AdvaMed has proposed a new Innovation Agenda.
While AZBio and its members recognize that the State of Arizona and the legislature must work diligently to balance the State Budget – which includes implementation of SB1475 and a 5% rate cut to providers of healthcare services – the end result may ultimately increase the state’s healthcare spend rather than reduce it.Continue reading
The success of the Jumpstart Our Business Startups (JOBS) Act in the biotech industry means that the work of the Subcommittee on Capital Markets and Government Sponsored Enterprises has taken on increased importance for emerging biotech companies. Current bills being considered could help to further support the search for breakthrough treatments at the next generation of emerging growth biotech companies.Continue reading
This Washington Update for CSBA is provided to AZBio Members as an update on issues that affect our industry at the nation’s capitol.Continue reading